Matthew Harrison
Stock Analyst at Morgan Stanley
(3.47)
# 884
Out of 5,129 analysts
710
Total ratings
49.65%
Success rate
4.16%
Average return
Main Sectors:
Stocks Rated by Matthew Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $768 → $769 | $778.97 | -1.28% | 59 | Feb 2, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $157 → $162 | $148.43 | +9.14% | 20 | Jan 30, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $151 → $150 | $155.80 | -3.72% | 44 | Jan 13, 2026 | |
| MRNA Moderna | Maintains: Equal-Weight | $30 → $28 | $40.51 | -30.88% | 27 | Dec 12, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $83 → $50 | $18.54 | +169.69% | 14 | Dec 12, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $149 → $156 | $191.20 | -18.41% | 56 | Dec 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $1,070 → $1,110 | $834.55 | +33.01% | 27 | Dec 4, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $37 → $41 | $27.31 | +50.13% | 16 | Dec 4, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $8 → $4 | $2.43 | +64.61% | 5 | Nov 12, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $104 → $98 | $60.31 | +62.49% | 23 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $30 | $19.69 | +52.36% | 13 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $4 | $0.36 | +1,025.18% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $460 → $439 | $461.24 | -4.82% | 41 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $20 | $17.96 | +11.36% | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Positive | $215 | $217.31 | -1.06% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6.2 → $6 | $4.46 | +34.53% | 10 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $5 | $0.68 | +635.62% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $40.87 | +37.02% | 2 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $55 | $32.48 | +69.33% | 2 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $3 | $1.93 | +55.84% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $23.56 | -53.31% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 | $1.77 | +295.48% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $32 | $30.06 | +6.45% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $19 | $3.45 | +450.72% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $1.61 | -37.89% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $10 | $22.48 | -55.52% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 → $8 | $10.87 | -26.37% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $44 | $34.09 | +29.07% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $3.88 | +235.05% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $80 | $24.34 | +228.68% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $60 | $5.02 | +1,095.22% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $203 → $216 | $109.38 | +97.48% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.92 | +27.55% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $3.10 | +61.29% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $182 | $220.89 | -17.61% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $9 | $22.91 | -60.72% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $282 | $366.58 | -23.07% | 38 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $210 | $322.28 | -34.84% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $52 | $27.73 | +87.52% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $175 → $173 | $240.86 | -28.17% | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $156 → $120 | $23.88 | +402.51% | 17 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $145 → $148 | $11.78 | +1,156.37% | 19 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $82 | $119.31 | -31.27% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $71 → $66 | $59.93 | +10.13% | 4 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $39 | $4.66 | +736.91% | 4 | Aug 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $46 | $44.25 | +3.95% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $35 | $7.69 | +355.14% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $207 → $275 | $1,015.21 | -72.91% | 2 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $3.32 | +472.29% | 1 | Jun 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $62 | $8.50 | +629.41% | 12 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $17.93 | -3.79% | 3 | Feb 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $89 → $83 | $98.84 | -16.03% | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $10 | $66.80 | -85.03% | 4 | Sep 10, 2018 |
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $768 → $769
Current: $778.97
Upside: -1.28%
Insmed
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $157 → $162
Current: $148.43
Upside: +9.14%
Gilead Sciences
Jan 13, 2026
Maintains: Overweight
Price Target: $151 → $150
Current: $155.80
Upside: -3.72%
Moderna
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $30 → $28
Current: $40.51
Upside: -30.88%
Legend Biotech
Dec 12, 2025
Maintains: Overweight
Price Target: $83 → $50
Current: $18.54
Upside: +169.69%
Biogen
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $149 → $156
Current: $191.20
Upside: -18.41%
argenx SE
Dec 4, 2025
Maintains: Overweight
Price Target: $1,070 → $1,110
Current: $834.55
Upside: +33.01%
Pharvaris
Dec 4, 2025
Maintains: Overweight
Price Target: $37 → $41
Current: $27.31
Upside: +50.13%
Zentalis Pharmaceuticals
Nov 12, 2025
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $2.43
Upside: +64.61%
BioMarin Pharmaceutical
Oct 28, 2025
Maintains: Overweight
Price Target: $104 → $98
Current: $60.31
Upside: +62.49%
Aug 18, 2025
Maintains: Overweight
Price Target: $33 → $30
Current: $19.69
Upside: +52.36%
Aug 12, 2025
Maintains: Overweight
Price Target: $6 → $4
Current: $0.36
Upside: +1,025.18%
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $460 → $439
Current: $461.24
Upside: -4.82%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $15 → $20
Current: $17.96
Upside: +11.36%
Jul 15, 2025
Initiates: Positive
Price Target: $215
Current: $217.31
Upside: -1.06%
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $6.2 → $6
Current: $4.46
Upside: +34.53%
Mar 12, 2025
Maintains: Overweight
Price Target: $15 → $5
Current: $0.68
Upside: +635.62%
Feb 18, 2025
Upgrades: Buy
Price Target: $56
Current: $40.87
Upside: +37.02%
Jan 31, 2025
Maintains: Buy
Price Target: $57 → $55
Current: $32.48
Upside: +69.33%
Nov 26, 2024
Downgrades: Underweight
Price Target: $10 → $3
Current: $1.93
Upside: +55.84%
Jun 21, 2024
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $23.56
Upside: -53.31%
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $1.77
Upside: +295.48%
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $30.06
Upside: +6.45%
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $3.45
Upside: +450.72%
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.61
Upside: -37.89%
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $22.48
Upside: -55.52%
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $10.87
Upside: -26.37%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $34.09
Upside: +29.07%
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $3.88
Upside: +235.05%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $140 → $80
Current: $24.34
Upside: +228.68%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $100 → $60
Current: $5.02
Upside: +1,095.22%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $109.38
Upside: +97.48%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.92
Upside: +27.55%
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $3.10
Upside: +61.29%
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $220.89
Upside: -17.61%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $22.91
Upside: -60.72%
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $366.58
Upside: -23.07%
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $322.28
Upside: -34.84%
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $27.73
Upside: +87.52%
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $240.86
Upside: -28.17%
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $23.88
Upside: +402.51%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $11.78
Upside: +1,156.37%
Nov 29, 2021
Maintains: Equal-Weight
Price Target: $88 → $82
Current: $119.31
Upside: -31.27%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $71 → $66
Current: $59.93
Upside: +10.13%
Aug 18, 2021
Maintains: Overweight
Price Target: $43 → $39
Current: $4.66
Upside: +736.91%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $51 → $46
Current: $44.25
Upside: +3.95%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $33 → $35
Current: $7.69
Upside: +355.14%
Aug 5, 2021
Maintains: Overweight
Price Target: $207 → $275
Current: $1,015.21
Upside: -72.91%
Jun 24, 2021
Initiates: Buy
Price Target: $19
Current: $3.32
Upside: +472.29%
Mar 8, 2021
Maintains: Overweight
Price Target: $67 → $62
Current: $8.50
Upside: +629.41%
Feb 24, 2021
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $17.93
Upside: -3.79%
Jan 6, 2020
Maintains: Equal-Weight
Price Target: $89 → $83
Current: $98.84
Upside: -16.03%
Sep 10, 2018
Assumes: Equal-Weight
Price Target: $10
Current: $66.80
Upside: -85.03%